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Acute kidney injury and thrombotic microangiopathy caused 
by malignant hypertension in a 21-year-old patient
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Abstract
The authors present a case of a severe cardiovascular emergency in a 21-year-old patient — malignant hypertension 
complicated by acute kidney injury and thrombotic microangiopathy.
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Introduction
Malignant hypertension (MH) is an emergency defined as 
severe hypertension with fundoscopic changes, that can 
be accompanied by acute deterioration in real function, 
encephalopathy or acute heart failure [1]. Its prevalence 
is estimated at 2–10/100,000/year [2, 3]. MH most com-
monly appears in patients with essential hypertension, 
but it may also be caused by renal, endocrine, vascular 
or rheumatoid diseases, as well as juxtaglomerular area 
neoplasms [4–6]. The 5-year survival rate in patients who 
underwent MH ranges from <5% (if the episode was left 
untreated) to 90% [3, 7]. Up to 35% of patients require hae-
modialysis or a kidney transplant. MH-associated mortality 
is estimated at 2.6/ 100 patient-years (whereas essential 
hypertension — 0.5/100 patient-years) and renal failure is 
the most common cause of death [6, 7]. This unfavourable 
outcome constitutes an important clinical issue.
Case report
A 21-year-old, previously untreated, obese man was admit-
ted to the Intensive Cardiological Care Unit with MH [blood 
pressure (BP) 250/150 mm Hg] and first symptoms of 
pulmonary oedema. Features of overhydration and basal 
crackles were noted. Anamnesis revealed high values of 
BP in the past 3 years (up to 180/100 mm Hg) and hea-
daches. Deterioration of exercise tolerance, dyspnoea and 
oedema of the lower limbs have been observed over the 
last 2–3 weeks.
Electrocardiography showed sinus tachyarrhythmia 
(115/min). Echocardiography revealed concentric hyper-
trophy of the left ventricle [(LV) 60/31 mm) and left atrium 
enlargement (51 mm) with mild decreased LV ejection fra-
ction [(LVEF); 50%] and diastolic dysfunction. Laboratory 
tests revealed impaired renal function and anaemia (Tab-
le 1). Abdominal ultrasound showed bilateral thickening of 
renal parenchyma up to 20 mm and increased echogeni-
city. Due to the deterioration of renal function, the patient 
was transferred to the Nephrology Clinic on the next day. 
Laboratory tests showed acute kidney injury (AKI). Mild hy-
pokalaemia was present. Blood tests revealed haemolytic 
anaemia and thrombocytopenia, suggesting thrombotic 
microangiopathy (TMA) (Table 1).
Due to suspicion of rapidly progressive glomerulo-
nephritis, antibody panel [extractable nuclear antigen 
(ENA), anti-glomerular basement membrane (anti-GBM), 
anti-neutrophil cytoplasmic antibodies (ANCA)] was con-
ducted, but the results were negative. Endocrine causes 
of MH were excluded. Haemolytic activity of complement 
elements was within normal limits (168.10 UEq/mL; 
N: 79.0–187.0 UEq/mL).
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retrieved. Normalization of BP values and improvement of 
platelet count was achieved. The patient was discharged 
with the recommendation of ambulatory care and one- 
-month follow-up. Amlodipine, ramipril, and methyldopa 
were ordered.
Follow-up laboratory tests revealed elevated creatinine 
and urea levels, as well as anaemia (Table 1). BP was sta-
bilized at an optimal level (120/90 mm Hg). The patient 
After BP was stabilized, a renal biopsy was performed. 
It revealed chronic nephropathy with focal glomerular scle-
rosis, stromal fibrosis and tubular atrophy. No deposits of 
immunoglobulins or complement elements were found. 
Full obliteration of arterioles’ lumen was observed, most 
likely due to MH.
Within the next days, the normalization of haemoly-
sis parameters was observed, but renal function was not 
Table 1. Laboratory test values
Parameter Intensive  
Cardiological  
Care Unit
Nephrology Clinic Normal range
On admission After therapy Follow-up  
laboratory tests
Bilirubin [mg/dL] 1,40 1,60 – 0,53 0,10–1,30
Bilirubin free – 1,28 – –
BNP [pg/mL] 2603,0 – – – 0,0–100,0
Calcium total [mEq/L] – – – 4,80 4,50–5,50
CK-MB [U/l] 22 – – – 0–39
Creatinine [mg/dL] 4,47 4,98 4,60 3,38 0,70–1,30
Creatinine clearence 
(MDRD) [mL/min]
18,2 – – – 75,0–110,0
CRP [mg/L] – 19,58 – 0,43 0,10–5,00
D-dimer [µg/L] 1672,0 – – – 0,0–500,0
Kalium [mEq/L] 3,20 3,20 5,00 5,70 3,50–5,20
Total protein [g/dL] 5,50 – – – 6,00–8,00
hs-troponin T [Ng/L] 92,8 – – – 0,0–14,1
Urine total protein [g/L] 4,11 1,35 0,51 0,35 0,05–0,08
Urea [mg/dL] 93 165 167 104 20–45
Uric acid [mg/dL] 8,50 – – – 3,40–7,00
RBC [M/µL] 3,01 2,76 3,41 3,0 3,90–5,70
Hb [g/dL] 9,3 8,4 10,9 9,3 13,0–17,2
Hct [%] 25,5 23,7 31,1 25,9 37–49,5
MCV [fL] 84,7 85,9 91,1 86,4 80,0–97,0
PLT [K/µL] 140 127 263 206 140,0–440,0
Reticulocytes [‰] – 57 – 10 5–15
Phosphor [mg/dL] – – 7,20 4,60 2,50–4,80
Ferritine [mg/mL] – – 678 710 20–300
LDH [U/L] – 782 488 142 120–230
PTH [pg/mL] – – 174 39 15–65
Proteinogram
Albumin [g/dL] 3,31 – – – 4,02–4,76
Gamma [g/dL] 0,53 – – – 0,80–1,35
Alpha1 [g/dL] 0,44 – – – 0,21–0,35
BNP — B-type natriuretic peptide, CK-MB — creatine kinase myocardial bound; MDRD — Modification of Diet in Renal Diseas; CRP — C-reactive protein; hs — high-sensitive; RBC — red blood cells; Hb — hemo-
globin; Hct — hematocrit; MCV — mean corpuscular volume; PLT — platelets; LDH — lactate dehydrogenase; PTH — parathormone
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was referred to a nephrological and cardiological outpatient 
clinic. Qualification for erythropoietin treatment was rec-
ommended if anaemia persisted. Antihypertensive therapy 
was maintained.
Discussion
The exact cause of MH in this patient is unknown. Endocrine 
and rheumatoid causes have been excluded. The patient 
might have suffered from essential hypertension, which 
caused chronic nephropathy and, left untreated, lead to 
MH or he might have developed renal pathology first that 
caused secondary hypertension resulting in progression 
of kidney injury. The results of the kidney biopsy remai-
ned inconclusive. Although some findings of the patient’s 
kidney biopsy were consistent with typical features of MH 
(narrowing of arterioles’ lumen) [6], others (focal glome-
rular sclerosis, stromal fibrosis, tubular atrophy) were 
non-specific and indicated that the renal pathology was 
chronic. However, the biopsy was not representative, as 
only 5 glomeruli were sampled.
AKI is frequent in MH, as 55% of patients may present 
with it and the only proteinuria may be present in 10% of 
patients [3]. MH may cause progression of kidney fun-
ction deterioration, even up to end-stage renal disease 
[3, 6], which is why the patient was ordered long-term 
nephrological follow-up. The degree of kidney injury seems 
to have a bigger impact on MH prognosis than the values 
of BP [2]. However, well-controlled BP in a long period can 
decrease the risk of further renal impairment [6]. Observed 
hypokalaemia (in contrast to hyperkalaemia, typically ob-
served in AKI) is caused by renal TMA, in which activated 
renin causes secondary hyperaldosteronism resulting in 
potassium excretion through kidneys.
Haematologic abnormalities in the course of MH require 
sensible approach, as it is important to distinguish between 
TMA and thrombotic thrombocytopenic purpura (TTP), since 
they may manifest similarly but their treatment is signifi-
cantly different- in TTP plasmapheresis is recommended, 
whereas patients suffering from MH-induced TMA respond 
well to hypertensive therapy [8]. Based on the lack of fe-
ver, relatively modest thrombocytopenia and the degree of 
kidney injury, the diagnosis of TMA was made and proper 
hypertensive treatment lead to improvement of haemato-
logic parameters. Although MH-induced TMA is associated 
with epithelial damage, its exact pathogenesis remains un-
known [8]. Some studies suggest the role of complement 
(especially alternative pathway) dysregulation [9], however, 
complement abnormalities were excluded in this case [3].
In summary, MH is a serious cardiovascular event of 
potential long-term complications that can occur also in 
young patients.
Streszczenie
Przedstawiono opis przypadku zagrażającego życiu stanu nagłego u 21-letniego pacjenta, jakim jest nadciśnienie złoś-
liwe powikłane ostrym uszkodzeniem nerek i mikroangiopatią zakrzepową.
Słowa kluczowe: nadciśnienie złośliwe, przełom nadciśnieniowy, ostre uszkodzenie nerek, mikroangiopatia 
zakrzepowa, stany nagłe
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